Will mTOR inhibitors make it as cancer drugs?

Cancer Cell

Volumn 4, Issue 5, 2003, Pages 343-348

  Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; TEMSIROLIMUS;

CELL GROWTH; HUMAN; INHIBITION KINETICS; KIDNEY CARCINOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIDE EFFECT;

EID: 0344063370     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00275-7     Document Type: Review

References (54)

1. Abraham R.T. Identification of TOR signaling complexes. More TORC for the cell growth engine Cell. 111:2002;9-12.
2. Allander S.V., Nupponen N.N., Ringner M., Hostetter G., Maher G.W., Goldberger N., Chen Y., Carpten J., Elkahloun A.G., Meltzer P.S. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res. 61:2001;8624-8628.
3. Aoki M., Blazek E., Vogt P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA. 98:2001;136-141.
4. Atkin, M.B., Hidalgo, M., Stadler W., Logan, T., Dutcher, J.P., Hudes, G., Park, Y., Marshall, B., Boni, J., and Dukart, G. (2002). A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 21:10a;36A.
5. Bianco R., Shin I., Ritter C.A., Yakes F.M., Basso A., Rosen N., Tsurutani J., Dennis P.A., Mills G.B., Arteaga C.L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 22:2003;2812-2822.
6. Choe G., Horvath S., Cloughesy T.F., Crosby K., Seligson D., Palotie A., Inge L., Smith B.L., Sawyers C.L., Mischel P.S. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63:2003;2742-2746.
7. Clark G.J., Kinch M.S., Rogers-Graham K., Sebti S.M., Hamilton A.D., Der C.J. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J. Biol. Chem. 272:1997;10608-10615.
8. Dancey J.E. Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. 16:2002;1101-1114.
9. Dancey J.E., Freidlin B. Targeting epidermal growth factor receptor-are we missing the mark? Lancet. 362:2003;62-64.
10. Douros J., Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev. 8:1981;63-87.
11. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S.C., Hafen E., Bos J.L., Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell. 11:2003;1457-1466.
12. Gera, J.F., Mellinghoff, I.K., Shi, Y., Rettig, M.B., Tran, C., Hsu, J.H., Sawyers, C.L., and Lichtenstein, A.K. (2003). AKT activity determines sensitivity to mTOR inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem., in press. Published online October 23, 2003. 10.1074/jbc. M309999200 .
13. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62:2002;6141-6145.
14. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis. involvement of vascular endothelial growth factor Nat. Med. 8:2002;128-135.
15. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 110:2002;177-189.
16. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 253:1991;905-909.
17. Hidalgo, M., Rowinsky, E., Erlichman, C., Drengler, R., and Marshall, B. (2000). CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. Proc. Am. Soc. Clin. Oncol. 19:10a:726A.
18. Hosoi H., Dilling M.B., Liu L.N., Danks M.K., Shikata T., Sekulic A., Abraham R.T., Lawrence J.C. Jr., Houghton P.J. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol. Pharmacol. 54:1998;815-824.
19. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22:2002;7004-7014.
20. Im E., von Lintig F.C., Chen J., Zhuang S., Qui W., Chowdhury S., Worley P.F., Boss G.R., Pilz R.B. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene. 21:2002;6356-6365.
21. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:2002;648-657.
22. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682.
23. Kenerson H.L., Aicher L.D., True L.D., Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62:2002;5645-5650.
24. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 110:2002;163-175.
25. Kwon C.H., Zhu X., Zhang J., Baker S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA. 100:2003;12923-12928. Published online October 8, 2003.
26. Long X., Spycher C., Han Z.S., Rose A.M., Muller F., Avruch J. TOR deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of mRNA translation. Curr. Biol. 12:2002;1448-1461.
27. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10:2002;151-162.
28. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346:2002;1773-1780.
29. Muise-Helmericks R.C., Grimes H.L., Bellacosa A., Malstrom S.E., Tsichlis P.N., Rosen N. Cyclin D expression is controlled post- transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 273:1998;29864-29872.
30. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA. 98:2001;10314-10319.
31. O'Donnell A., Faivre S., Judson I., Delbado C., Brock C., Lane H., Shand N., Hazell K., Armand J.-P., and Raymond E. (2003). A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc. Am. Soc. Clin. Oncol. 22: 200 (abstract 803).
32. Oldham S., Montagne J., Radimerski T., Thomas G., Hafen E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 14:2000;2689-2694.
33. Peng T., Golub T.R., Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol. 22:2002;5575-5584.
34. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA. 98:2001;10320-10325.
35. Potter C.J., Pedraza L.G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4:2002;658-665.
36. Radimerski T., Montagne J., Rintelen F., Stocker H., van der Kaay J., Downes C.P., Hafen E., Thomas G. dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat. Cell Biol. 4:2002;251-255.
37. Rajasekhar V.K., Viale A., Socci N.D., Wiedmann M., Hu X., Holland E.C. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell. 12:2003;889-901.
38. Raymond, E., Alexandre, J., Depenbrock, H., Mekhaldi, S., Angevin, E., Hanauske, A., Baudin, E., Escudier, B., Frisch, J., Boni, J., and Armand, J.P. (2000). CCI-779, a rapamycin analog with antitumor activity: A phase I study utilizing a weekly schedule. Proc. Am. Soc. Clin. Oncol. 19 (abstract 728).
39. Sawyers C.L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. in press:2003.
40. Saucedo L.J., Gao X., Chiarelli D.A., Li L., Pan D., Edgar B.A. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol. 5:2003;566-571.
41. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell. 103:2000;253-262.
42. Shai R., Shi T., Kremen T.J., Horvath S., Liau L.M., Cloughesy T.F., Mischel P.S., Nelson S.F. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 22:2003;4918-4923.
43. Shamji A.F., Kuruvilla F.G., Schreiber S.L. Partitioning the transcriptional program induced by rapamycin among the effectors of the Tor proteins. Curr. Biol. 10:2000;1574-1581.
44. Shamji A.F., Nghiem P., Schreiber S.L. Integration of growth factor and nutrient signaling. implications for cancer biology Mol. Cell. 12:2003;271-280.
45. She Q.B., Solit D., Basso A., Moasser M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 9:2003;4340-4346.
46. Shi Y., Gera J., Hu L., Hsu J.H., Bookstein R., Li W., Lichtenstein A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62:2002;5027-5034.
47. Stocker H., Radimerski T., Schindelholz B., Wittwer F., Belawat P., Daram P., Breuer S., Thomas G., Hafen E. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 5:2003;559-565.
48. Takuwa N., Fukui Y., Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol. Cell. Biol. 19:1999;1346-1358.
49. Vivanco I., Sawyers C.L. The phosphophatidylinositol 3-kinase/AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501.
50. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349:2003;427-434.
51. Yu Y., Sato J.D. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J. Cell. Physiol. 178:1999;235-246.
52. Zhang H., Stallock J.P., Ng J.C., Reinhard C., Neufeld T.P. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 14:2000;2712-2724.
53. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5:2003;578-581.
54. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells. implications for tumor angiogenesis and therapeutics Cancer Res. 60:2000;1541-1545.